Summary: In this CME activity, experts in lung cancer discuss the current and evolving role of molecularly targeted therapies in NSCLC. Clinical data on anti-VEGF and anti-EGFR therapies are assessed, and practical considerations for optimal integration of these agents into standard treatment for NSCLC are discussed. Unanswered questions regarding the role of targeted therapies and future research directions are described as well.
